Biopharma Dealmaking Quarterly Statistics, Q3 2014

A look at financing, M&A, and alliance activity July–September 2014

Biopharma financing dropped 22% in Q3 to $5.65 billion. In the largest M&A, Roche bulked up on rare diseases, gaining Esbriet through its $8 billion takeover of InterMune; Sanofi dominated in alliance dealmaking.

During the third quarter of 2014, biopharma financing declined 22% to $5.65 billion, compared with the $7.2 billion raised in Q2. (See Exhibit 1.) With $2.2 billion in deal volume, Q3 initial public offerings knocked follow-on public offerings (which brought in a total of $874 million in Q3) down from the top position, where they had been for the past two consecutive quarters.

Exhibit 1

More from Deal-Making

More from In Vivo